Xalkori (crizotinib capsules and oral pellets) — Cigna
Inflammatory Myofibroblastic Tumor (ALK-positive)
Initial criteria
- Patient age ≥ 1 year
- Patient has anaplastic lymphoma kinase (ALK)-positive disease
- Patient has advanced, recurrent, or metastatic disease OR tumor is inoperable
Approval duration
1 year